Effects of everolimus on cellular and humoral immune processes leading to chronic allograft nephropathy in a rat model with sensitized recipients

Transplantation

Volumn 83, Issue 4, 2007, Pages 498-505

  Koch, Martina ^a   Mengel, Michael ^a   Poehnert, Daniel ^a   Nashan, Bjoern ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Alloantibodies; Chronic allograft nephropathy; Everolimus; Rat model

Indexed keywords

ALBUMIN; ALLOANTIBODY; CREATININE; EVEROLIMUS; ANTIBODY; DRUG DERIVATIVE; HLA ANTIGEN CLASS 1; RAPAMYCIN;

ACUTE GRAFT REJECTION; ACUTE KIDNEY TUBULE NECROSIS; ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLOGICAL MONITORING; CD4+ T LYMPHOCYTE; CELL INFILTRATION; CELLULAR IMMUNITY; CHRONIC ALLOGRAFT NEPHROPATHY; CHRONOTHERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE MODEL; DRUG EFFECT; EXPERIMENTAL MODEL; GLOMERULOSCLEROSIS; GRAFT RECIPIENT; HISTOPATHOLOGY; HUMORAL IMMUNITY; KIDNEY DONOR; KIDNEY FUNCTION; KIDNEY INTERSTITIUM; KIDNEY TRANSPLANTATION; KIDNEY TUBULE; LEWIS RAT; LYMPHOCYTE COUNT; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; NONHUMAN; NUDE RAT; PERIPHERAL LYMPHOCYTE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RAT; SENSITIZATION; SURVIVAL TIME; URINARY EXCRETION; ALLOTRANSPLANTATION; ANIMAL; ANTIBODY PRODUCTION; CHRONIC DISEASE; GRAFT REJECTION; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; KIDNEY DISEASE; PATHOLOGY; PATHOPHYSIOLOGY; SURVIVAL RATE;

ANIMALS; ANTIBODIES; ANTIBODY FORMATION; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; GRAFT REJECTION; HISTOCOMPATIBILITY ANTIGENS CLASS I; IMMUNOHISTOCHEMISTRY; KIDNEY DISEASES; LYMPHOCYTE COUNT; MALE; RATS; SIROLIMUS; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS;

EID: 33947543050     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000252779.56951.bf     Document Type: Article

References (40)

1. Paul LC. Chronic allograft nephropathy. Kidney Int 1999; 56: 783.
2. Halloran PF, Melk A, Barth C. Rethinking chronic allograft nephropathy: The concept of accelerated senescence. J Am Soc Nephrol 1999; 10: 167.
3. Vazquez MA. Chronic rejection of renal transplants: New clinical insights. Am J Med Sci 2000; 320: 43.
4. Ponticelli C. Progression of renal damage in chronic rejection. Kidney Int 2000; 57(Suppl 75): 62.
5. Hariharan S. Long-term kidney transplant survival. Am J Kidney Dis 2001; 38.
6. Murray BM, Paller MS, Ferris TF. Effect of cyclosporine administration on renal hemodynamics in conscious rats. Kidney Int 1985; 28: 767.
7. Kahanna A, Plummer M, Bromberek C. Expression of TGF-beta and fibrogenic genes in transplant recipients with tacrolimus and cyclosporine nephrotoxicity. Kidney Int 2002; 62: 2257.
8. Nitta K, Friedman AL, Nicastri AD, et al. Granular juxtaglomerular cell hyperplasia caused by cyclosporine. Transplantation 1987; 44: 417.
9. Teraski PI, Ozawa M. Predicting Kidney Graft failure by HLA antibodies: a prospective trial. Am J Transpl 2004; 4: 438.
10. Süsal C, Opelz G. Kidney graft failure and presensitization against HLA class I and Class II antigens. Transplantation 2002; 73: 1269.
11. Joosten SA, van Kooten C, Paul LC. Pathogenesis of chronic allograft nephropathy. Transpl Int 2003; 16: 137.
12. Koch M, Joosten SA, Mengel M, et al. Adoptive transfer of primed CD4+ T-Lymphocytes induces pattern of chronic allograft nephropathy in a nude rat model. Transplantation 2005; 79: 753.
13. Doege C, Koch M, Heratizadeh A, et al. Chronic allograft nephropathy in nude rats after adoptive transfer of primed T lymphocytes. Transplant Int 2005; 18: 981.
14. Neumayer H-H. Introducing Everolimus (Certican) in organ transplantation: An Overview of preclinical and early clinical developments. Transplantation 2005; 79: S72.
15. Böhler T, Waiser J, Budde K, et al. The in vivo effect of rapamycin derivate SDR RAD on lymphocyte proliferation. Transpl Proc 1998; 30; 2195.
16. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivate. Pharmacological properties in vitro and in vivo. Transplantation 1997; 64: 36.
17. Kim MS, Park J, Ha H, et al. Rapamycin inhibits platelet-derived growth factor-induced collagen, but not fibronection, synthesis in rat mesangial cells. Yonsei Med J 2004; 6: 1121.
18. Lutz J, Zou H, Liu S, et al. Apoptosis and treatment of chronic allograft nephropathy with everolimus. Transplantation 2003; 76: 508.
19. Mason D, Arthur RP, Dallman MJ, et al. Functions of rat T-lymphocyte subsets isolated by means of monoclonal antibodies. Immunol Rev 1983; 74: 57.
20. Solez K, Axelsen RA, Benediktsson H, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411.
21. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
22. Hünig T, Wallny HJ, Hartley JK, et al. A monoclonal antibody to a constant determinant of the rat T cell antigen receptor that induces T cell activation: differential reactivity with subsets of immature and mature T lymphocytes. J Exp Med 1989; 169: 73.
23. Demirci G, Nashan B, Pichlmayr R. Fibrosis in chronic rejection of human liver allografts. Transplantation 1996; 62: 1776.
24. McKenna RM, Takemoto SK, Terasakti PI. Anti-HLA antibodies after solid organ transplantation. Transplantation 2000; 69: 319.
25. Lederer SR, Kluth-Pepper B, Schneeberger H, et al. Impact of humoral alloreactivity early after transplantation on the long-term survival of renal allografts. Kiney Int 2001; 59: 334.
26. Piazza A, Poggi E, Borrelli L, et al. Impact of donor-specific antibodies on chronic rejection occurance and graft loss in renal transplantation: posttransplant analysis using flow cytometric techniques. Transplantation 2001; 71: 1106.
27. Martin L, Guignier F, Mousson Ch, et al. Detection of donor-specific anti HLA-antibodies with flow cytometry in eluates and sera from renal transplant recipients with chronic allograft nephropathy.
28. Sumitran-Holgersson S. HLA-specific alloantibodies and renal graft outcome. Nephrol Dial Transplant 2001; 16: 897.
29. Joosten SA, Sijpkens YW, van Ham V, et al. Antibody response against the glomerular basement membrane protein agrin in patients with transplant glomerulopathy. Am J Transpl 2005; 5: 383.
30. Viklicky O, Zou H, Mueller V, et al. SDZ-RAD prevents manifestation of chronic rejection in rat renal allografts. Transplantation 2000; 69: 497.
31. Sedrani R, Cottens S, Kallen J, et al. Chemical modification of rapamycin; the discovery of SDZ-RAD. Transplant Proc 1998; 30: 2192.
32. Salas-Prato M, Assalian A, Mehdi AZ, et al. Inhibition by rapamycin of PDGF- and bTGF- induced human tendon fibroblast proliferation in vitro. J Glaucoma 1996; 5: 54.
33. Azzola A, Havryk A, Chhajed P, et al. Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation. Transplantation 2004; 77: 275.
34. McGrath JS, Shehata M. The effect of differing immunosuppressive regimens on the functional and morphologic changes in a rat renal allograft model of chronic rejection. Transplant Proc 2001; 33: 2191.
35. Lawsin L, Light JA. Severe acute renal failure after exposure to sirolimus-tacrolimus in two living donor kidney recipients. Transplantation 2003; 75: 157.
36. Ferenza FC, Fitzpatrick PM, Mertz J, et al. for the Mayo Nephrology Collaborative Group. Acute rapamycin nephrotocicity in native kidneys of patients with chronic glomerulopathies. Nephrol Dial Transpant 2004; 19: 1288.
37. Dittrich E, Schmaldienst S, Soleiman A, et al. Rapamycin-associated post transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy. Transpl Int 2004; 17: 215.
38. Marti H-P, Frey FJ. Nephrotoxicity of rapamycin: an emerging problem in clinical medicine. Nephrol Dial Transplant 2005; 20: 13.
39. Daniel C, Renders L, Amann K, et al. Mechanisms of Everolimus-induced glomerulosclerosis after glomerular injury in the rat. Am J Transplant 2005; 5: 2849.
40. Daniel C, Pippin J, Shankland SJ, Hugo C. The rapamycin derivate RAD inhibitis mesangial cell migration through the CDK-inhibitor p27KIP1. Lab Invest 2004; 84: 588.